These findings suggest that while MYC modulation can influence the response to DYRK1A inhibition in specific KMT2A-R ALL cell lines, its effects are not broadly consistent across all tested models, highlighting the complexity of MYC’s role in ALL. Here, KMT2A is linked to acute lymphoblastic leukemia.